Coupang Inc vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Coupang Inc trades at $15.83 (market cap $27.70B), while Nuvation Bio Inc. Class A Common Stock trades at $5.03 (market cap $1.74B). The key difference: Coupang Inc is far larger — about 15.9× Nuvation Bio Inc. Class A Common Stock's market cap, and Nuvation Bio Inc. Class A Common Stock is trading nearer its 52-week high, Coupang Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coupang Inc for 55 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| CPNG | NUVB | |
|---|---|---|
Market Cap | $27.70B | $1.74B |
Volume | 27,703,608 | 9,289,619 |
Sector | Consumer Cyclical | Health |
52-Week High | $32.47 | $9.54 |
52-Week Low | $13.75 | $3.41 |
Typical Hold Time | 55 Days | 0 Days |
Enterprise Value | $27.22B | $1.33B |
Signals from Pluang's Aura AI — not financial advice
CPNG trades at $15.83, up 6.89% over 24 hours, with a bullish technical signal from moving averages and ADX. The company reported $34.53B revenue in 2025 with a net income of $208M, though recent quarters show earnings misses. Analyst consensus is strongly bullish with a $25.25 price target, and cash flow from operations remains positive at $1.77B.
The outlook is mixed: strong revenue growth and analyst support offer upside, but negative net income margin and high P/E of 184.18 signal overvaluation risks. Key risks include competitive pressure from MercadoLibre and Alibaba, and a projected net loss of $767M in 2026. Institutional sentiment is positive, but earnings volatility requires caution.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →